Healthcare provider profile · identity verified

Vipulkumar G. Patel, M. D.

Internal Medicine · DICKINSON, TX · NPI 1710987995

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	398	125
Losartan Potassium	Losartan Potassium	345	98
Amlodipine Besylate	Amlodipine Besylate	312	100
Rosuvastatin Calcium	Rosuvastatin Calcium	306	104
Levothyroxine Sodium	Levothyroxine Sodium	230	71
Metformin Hcl	Metformin Hcl	211	60
Alendronate Sodium	Alendronate Sodium	207	61
Metoprolol Tartrate	Metoprolol Tartrate	172	53
Hydrochlorothiazide	Hydrochlorothiazide	150	40
Pantoprazole Sodium	Pantoprazole Sodium	144	55
Allopurinol	Allopurinol	141	40
Albuterol Sulfate Hfa	Albuterol Sulfate	125	42
Gabapentin	Gabapentin	115	46
Glimepiride	Glimepiride	114	32
Furosemide	Furosemide	113	39
Simvastatin	Simvastatin	112	33
Carvedilol	Carvedilol	105	39
Montelukast Sodium	Montelukast Sodium	104	33
Omeprazole	Omeprazole	104	35
Lisinopril	Lisinopril	90	30
Tamsulosin Hcl	Tamsulosin Hcl	90	29
Olmesartan Medoxomil	Olmesartan Medoxomil	87	28
Metoprolol Succinate	Metoprolol Succinate	83	26
Clopidogrel	Clopidogrel Bisulfate	78	25
Pravastatin Sodium	Pravastatin Sodium	77	25
Potassium Chloride	Potassium Chloride	64	23
Famotidine	Famotidine	56	21
Atenolol	Atenolol	55	17
Jardiance	Empagliflozin	54	13
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	45	19
Hydralazine Hcl	Hydralazine Hcl	44	15
Tizanidine Hcl	Tizanidine Hcl	43	20
Fenofibrate	Fenofibrate	42	15
Synthroid	Levothyroxine Sodium	42	13
Trazodone Hcl	Trazodone Hcl	41	12
Escitalopram Oxalate	Escitalopram Oxalate	38	14
Azithromycin	Azithromycin	36	34
Donepezil Hcl	Donepezil Hcl	35	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	11
Lovastatin	Lovastatin	35	suppressed
Ozempic	Semaglutide	35	suppressed
Mirtazapine	Mirtazapine	34	14
Ezetimibe	Ezetimibe	33	suppressed
Fluticasone Propionate	Fluticasone Propionate	33	17
Pioglitazone Hcl	Pioglitazone Hcl	33	13
Sertraline Hcl	Sertraline Hcl	32	11
Tradjenta	Linagliptin	30	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	29	26
Buspirone Hcl	Buspirone Hcl	28	12
Mounjaro	Tirzepatide	27	suppressed
Meclizine Hcl	Meclizine Hcl	26	suppressed
Nifedipine Er	Nifedipine	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Memantine Hcl	Memantine Hcl	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	19
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Finasteride	Finasteride	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Glipizide	Glipizide	19	suppressed
Valsartan	Valsartan	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Mupirocin	Mupirocin	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	13
Clonidine Hcl	Clonidine Hcl	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Combivent Respimat	Ipratropium/Albuterol Sulfate	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Olanzapine	Olanzapine	12	suppressed
Acarbose	Acarbose	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error